- Home
- SRZN vs ALEC Comparison
SRZN vs ALEC Comparison
Compare SRZN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- ALEC
- Stock Information
- Founded
- SRZN 2015
- ALEC 2013
- Country
- SRZN United States
- ALEC United States
- Employees
- SRZN N/A
- ALEC N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRZN Health Care
- ALEC Health Care
- Exchange
- SRZN Nasdaq
- ALEC Nasdaq
- Market Cap
- SRZN 120.0M
- ALEC 124.0M
- IPO Year
- SRZN N/A
- ALEC 2019
- Fundamental
- Price
- SRZN $13.06
- ALEC $1.44
- Analyst Decision
- SRZN Strong Buy
- ALEC Hold
- Analyst Count
- SRZN 2
- ALEC 9
- Target Price
- SRZN $38.50
- ALEC $3.40
- AVG Volume (30 Days)
- SRZN 38.1K
- ALEC 5.1M
- Earning Date
- SRZN 11-07-2025
- ALEC 11-06-2025
- Dividend Yield
- SRZN N/A
- ALEC N/A
- EPS Growth
- SRZN N/A
- ALEC N/A
- EPS
- SRZN N/A
- ALEC N/A
- Revenue
- SRZN $12,621,000.00
- ALEC $81,130,000.00
- Revenue This Year
- SRZN N/A
- ALEC N/A
- Revenue Next Year
- SRZN N/A
- ALEC $290.64
- P/E Ratio
- SRZN N/A
- ALEC N/A
- Revenue Growth
- SRZN N/A
- ALEC 46.77
- 52 Week Low
- SRZN $5.90
- ALEC $0.87
- 52 Week High
- SRZN $18.17
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- SRZN 45.71
- ALEC 27.00
- Support Level
- SRZN $13.42
- ALEC $1.45
- Resistance Level
- SRZN $14.38
- ALEC $1.68
- Average True Range (ATR)
- SRZN 0.42
- ALEC 0.20
- MACD
- SRZN -0.12
- ALEC -0.13
- Stochastic Oscillator
- SRZN 5.63
- ALEC 5.31
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.